Pain Management in Persons with a Substance Related Disorder (SRD)
Updates in Infectious Disease—Management of Multidrug Resistant Gram-Negative Infections
Updates in Renal Disease—Evaluation and Management of Chronic Kidney Disease
Updates in Cardiac Disease—Evaluation and Management of Heart Failure

• Series Overview
• Program Content
• Faculty
• Financial Relationship Disclosures
• Target Audience and Learning Objectives
• Continuing Pharmacy Education Credit
• BCPS Specialty Recertification Credit
• Technical Requirements
• Commercial Support
• Fees

The Clinical Reasoning Series in Pharmacotherapy has been approved by the Board of Pharmacy Specialties (BPS) as one component of the professional development programs developed by ACCP for recertification of the Board Certified Pharmacotherapy Specialist (BCPS).

This educational series explores cutting-edge, contemporary therapeutic topics, and demonstrates scientifically sound clinical reasoning and decision-making. It employs learning activities designed to advance the participants' skills and abilities to critically evaluate the scientific evidence and effectively incorporate significant findings into daily practice that lead to effective and safe patient care.

The program will consist of several educational activities and is presented in four parts with each part containing:

• streaming audio/slide synchronized presentations
• downloadable mp3 audio files
• downloadable mp4 video files
• downloadable/printable PDFs of presentation slides
• Continuing Pharmacy Education (CPE) credit
• Recertification Credit - Available with Specialty Recertification package

Release date: December 12, 2023
BCPS credit expiration date: December 12, 2024
ACPE credit expiration date: November 14, 2026

Pain Management in Persons with a Substance Related Disorder (SRD)

Pain Management in Persons with a Substance Related Disorder (SRD) will explore cutting-edge, contemporary therapeutic pain-management topics and demonstrate scientifically sound clinical reasoning and decision-making within the realm of Substance Related Disorder. The speaker will review options, including non-opioid medications and therapies, for those with an SRD and Opioid Use Disorder (OUD), and examine current barriers to treatment. Pharmacotherapy specialists should leave the presentation with a better understanding of SRD and the use of non-stigmatize language and gain a clear understanding of Medication Assisted Treatment (MAT) options and patient-specific considerations during initiation and follow up.

This program will explore the following topics:

• The practice of person-first non-stigmatizing language
• Chronic pain and Long Term Opioid Therapy (LTOT) in persons with an SRD
• Barriers to Medication Assisted Treatment (MAT) for chronic pain and OUD
• Treatment plans for the transition to buprenorphine
• Perioperative pain management strategies for persons with OUD on buprenorphine

Updates in Infectious Disease—Management of Multidrug Resistant Gram-Negative Infections

Updates in Infectious Disease—Management of Multidrug Resistant Gram-Negative Infections will include a review of gram-negative organisms and resistance mechanisms, a comparison of current treatment guidelines, consensus statements, and literature, an evaluation of pharmacotherapy options, and the design of individualized treatment plans. Pharmacists must be familiar with the identification of these organisms, compare potential treatment options, and design effective individualized therapies for patients with multidrug-resistant gram-negative infections.

This program will explore the following topics:

• Identifying clinically significant gram-negative organisms and infection types
• Resistance mechanisms of multi-drug resistant (MDR) gram-negative bacteria
• Novel beta-lactams and beta-lactam inhibitor combination antibiotics
• Therapeutic regimens for treatment of MDR gram-negative infections

Updates in Renal Disease—Evaluation and Management of Chronic Kidney Disease

Updates in Renal Disease—Evaluation and Management of Chronic Kidney Disease will focus on the evolution of kidney function assessment equations and differences between evaluation methods, the role of pharmacologic agents in reducing chronic kidney disease progression, and the application of medication decision-making. Knowing how to apply kidney function equations to determine the severity of CKID and identifying safe and effective treatment is critical, and pharmacists who can use this knowledge to design patient-specific treatment plans to enhance or preserve kidney function can positively impact the outcomes of CKD patients.

This program will explore the following topics:

• Equations for estimating kidney function
• Methods used to evaluate kidney function
• Sodium-glucose cotransporter-2 inhibitors and renin-angiotensin-aldosterone system inhibitors
• Treatment regimens aimed at slowing the progression of CKD

Updates in Cardiac Disease—Evaluation and Management of Heart Failure

Updates in Cardiac Disease—Evaluation and Management of Heart Failure will focus on the classifications and stages of heart failure, medications used to treat and avoid in treating heart failure, evaluate clinical practice guidelines, and develop evidence-based treatment regimens. Because pharmacists are responsible for developing appropriate and effective patient-specific treatment plans, early identification of potential challenges or complications caused by introducing new medications is a crucial skill.

This presentation has been created by Dr. Ashley Schenk and was presented at the ACCP 2023 Annual Meeting by Dr. Sara Brouse.

This program will explore the following topics:

• The classifications and four stages of heart failure
• Medications used to treat heart failure and those that may cause or exacerbate heart failure
• Guidelines and recommendations
• Evidence-based treatment regimens for a patient with heart failure

Clinical Reasoning Series in Pharmacotherapy - Program Chair

	Jackie P. Rowe, Pharm.D., BCPS Medical Science Liason Sanofi Hoboken, New Jersey

Pain Management in Persons with a Substance Related Disorder (SRD)

	Rebecca Hoss, Pharm.D., BCPP Senior Substance Use Disorder/Pain Pharmacist UC Davis Health Ticon 1 Davis, California

Updates in Infectious Disease—Management of Multidrug Resistant Gram-Negative Infections

	Akshith Dass, Pharm.D., BCIDP, BCPS Infectious Diseases Clinical Coordinator Cleveland Clinic Mercy Hospital Akron, Ohio

Updates in Renal Disease—Evaluation and Management of Chronic Kidney Disease

	Rachel Khan, Pharm.D., BCPS Associate Professor Virginia Commonwealth University School of Pharmacy Richmond, Virginia

Updates in Cardiac Disease—Evaluation and Management of Heart Failure

	Ashley Schenk, Pharm.D., BCCP, BCPS, AACC Cardiology Clinical Pharmacist UK HealthCare Assistant Adjunct Professor University of Kentucky College of Pharmacy Lexington, Kentucky
	Sara D. Brouse, Pharm.D., FCCP, FACC, BCCP, BCPS Regional Dean & Professor TTUHSC Jerry H Hodge School of Pharmacy Cardiology Clinical Pharmacist Hendrick Medical Center Abilene, Texas

We thank the following peer reviewers for lending their time and expertise to this Clinical Reasoning Series in Pharmacotherapy.

Disclosures 

TARGET AUDIENCE
The target audience for Clinical Reasoning Series in Pharmacotherapy is the pharmacist practicing in a clinical setting as a Board Certified Pharmacotherapy Specialist (BCPS) looking to earn recertification credit, and those clinicians seeking additional information on the topics covered.

LEARNING OBJECTIVES
Pain Management in Persons with a Substance Related Disorder (SRD):

1. Practice person-first non-stigmatizing language in the treatment of chronic pain and Substance Related Disorders (SRDs).
2. Review the treatment of chronic pain with Long Term Opioid Therapy (LTOT) in persons with an SRD.
3. Examine barriers to Medication Assisted Treatment (MAT) for chronic pain and Opioid Use Disorder (OUD).
4. Design a treatment plan for the transition to buprenorphine in persons newly diagnosed with an SRD.
5. Formulate perioperative pain management strategies for persons with OUD on buprenorphine undergoing surgery.

Updates in Infectious Disease—Management of Multidrug Resistant Gram-Negative Infections:

1. Identify clinically significant gram-negative organisms and infection types.
2. Describe resistance mechanisms of multi-drug resistant (MDR) gram-negative bacteria including extended spectrum beta-lactamases (ESBLs), AmpC beta-lactamase, carbapenem resistance, and difficult-to-treat resistance mechanisms.
3. Evaluate guidelines for the treatment of MDR gram-negative infections.
4. Compare novel beta-lactams and beta-lactam inhibitor combination antibiotics used in the treatment of MDR gram-negative infections.
5. Design appropriate therapeutic regimens for treatment of MDR gram-negative infections.

Updates in Renal Disease—Evaluation and Management of Chronic Kidney Disease:

1. Outline the evolution of equations for estimating kidney function.
2. Differentiate methods used to evaluate kidney function.
3. Apply estimation of kidney function equations to medication-related decision-making.
4. Evaluate the use of sodium-glucose cotransporter-2 inhibitors and renin-angiotensin-aldosterone system inhibitors in chronic kidney disease (CKD).
5. Design an evidence-based treatment regimen aimed at slowing the progression of CKD.

Updates in Cardiac Disease—Evaluation and Management of Heart Failure:

1. Differentiate between the classifications and four stages of heart failure.
2. Identify medications that may cause or exacerbate heart failure.
3. Evaluate current practice guidelines and consensus recommendations for the treatment of heart failure.
4. Compare medications used in the treatment of heart failure.
5. Develop an evidence-based treatment regimen for a patient with heart failure.

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pain Management in Persons with a Substance Related Disorder (SRD)
Activity Number: 0217-0000-23-120-H01-P
Contact Hours: 1.50
Activity Type: Application-Based Activity

Updates in Infectious Disease—Management of Multidrug Resistant Gram-Negative Infections
Activity Number: 0217-0000-23-121-H01-P
Contact Hours: 1.50
Activity Type: Application-Based Activity

Updates in Renal Disease—Evaluation and Management of Chronic Kidney Disease
Activity Number: 0217-0000-23-122-H01-P
Contact Hours: 1.50
Activity Type: Application-Based Activity

Updates in Cardiac Disease—Evaluation and Management of Heart Failure
Activity Number: 0217-0000-23-123-H02-P
Contact Hours: 1.50
Activity Type: Application-Based Activity

Methods and CE Requirements

Continuing Pharmacy Education Credit

Activities consist of audio/video/PDF files, attestation statements, and activity evaluations. Learners must purchase the product, review all content, complete the attestation statements and course evaluations to receive continuing pharmacy education credit for each activity. You must submit the attestation statements and course evaluations associated with each activity within the course by November 14, 2026.

National Association of Boards of Pharmacy - CPE Monitor Service

Provided through the collaborative efforts of the National Association of Boards of Pharmacy (NABP), the Accreditation Council for Pharmacy Education (ACPE), and ACPE-accredited providers, the CPE Monitor Service allows you to electronically keep track of continuing pharmacy education (CPE) credits from ACPE-accredited providers. ACPE-accredited providers, like ACCP, are responsible for transmitting this information to NABP to be stored in the CPE Monitor system. Statements of credit will be available at CPE Monitor, nabp.pharmacy/cpe-monitor-service/, within 2–3 business days after completion of this activity. For more information on CPE Monitor please visit nabp.pharmacy/cpe-monitor-service/.

To transfer these credits to CPE Monitor on your behalf your NABP e-Profile ID Number and date of birth must be listed on your ACCP account. To verify or update this information in your ACCP account, visit Licensure/Certification. Be sure to save your changes at the bottom of the page.

Some international pharmacists do not use the CPE Monitor service. To verify or update this information in your ACCP account, visit Licensure/Certification. Check the box “I am an international pharmacist or I am not licensed to practice in the United States, and do not have an NABP e-Profile ID.” Be sure to save your changes at the bottom of the page.

To be eligible to earn BCPS recertification credit, learners must purchase the recertification version of this course, review all content, successfully complete, submit and pass the web-based posttest associated with each activity within the course by December 12, 2024. You are allowed only one attempt to successfully complete this assessment.

The passing point to earn BCPS recertification credit is based on an expert analysis of the assessment items in each posttest activity. Any posttest submitted before the BCPS posttest deadline that meets this passing point will earn BCPS recertification credits. These credits will be assigned as of the date of test submission.

All participants must have a Board of Pharmacy Specialties (BPS) board certification credential number, BPS ID Number, and a BPS expiration date on file with ACCP for reporting purposes. To verify or update this information in your ACCP account, visit Licensure/Certification. Be sure to save your changes at the bottom of the page.

For statements of recertification credit, visit www.bpsweb.org. Questions regarding the number of hours required for BCPS recertification should be directed to BPS at (202) 946-5026 or www.bpsweb.org.

The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs.

• Internet browser
• Adobe Reader (available free)

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.